FMC's 20% Bounce Is a Short Squeeze, Not a Bottom

FMC is dead and yet, suddenly, it isn't. Over the past year the crop-protection maker lost roughly two-thirds of its value, tumbling from a $38.67 high to a $9.95 low in the slump. Then it snapped back — up more than 20% in a month, back to about $12.90 — the kind of violent rebound that gets pitched as a "terrific short-squeeze idea at the industry bottom." Before anyone agrees, it's worth separating two very different claims hiding inside that pitch: whether the stock bounced, which it clearly did, and whether the business bottomed, which the evidence does not yet support.

What actually moved the price

Start with the price side, because it explains the squeeze. Roughly a tenth of the float was short as of late last year, with several days to cover — heavy negative positioning sitting on a beaten-down stock. When a catalyst lands on that pile, covering alone can move the tape.

The catalyst landed on June 30, when FMC concluded its strategic review not with a sale but with a $400 million minority equity investment from Belgian industrial group Tessenderlo at $13.30 a share, roughly a fifth of the company. The stock jumped in response. That is a real, dilutive vote of confidence from a willing buyer, but it is funding and stability, not an inflection in demand.

Where the business actually stands

The accounting for the business is less flattering. In the second quarter, revenue fell 17% year over year to $867 million, and down 20% excluding the divested India business. Adjusted earnings per share were $0.26, down 62%. There is a genuine bright spot — adjusted EBITDA of $153 million came in above the high end of guidance, and cash generation looked solid — but a big chunk of that cash flow was a one-time $200 million upfront licensing payment from Cortevafor the rimisoxafen asset.

The decisive number is the guidance management just cut, and cut again. Full-year 2026 adjusted EPS is now guided to $1.19–$1.49, down about 55%, with revenue and EBITDA guided lower too. And the near-term is the worst of it: the third quarter is guided to adjusted EPS of just $0.05–$0.13, roughly a 90% collapse, as management blames a "more challenging macro environment"and customers pulling orders. When a company guides the next quarter down 90%, the bottom is not something you can assume from a chart.

The part that isn't cyclical

This is where the "industry bottom" framing runs into trouble. The ag input market is genuinely weak, but FMC carries a company-specific problem on top. Its flagship insecticide, Rynaxypyr (chlorantraniliprole), is the product that built the crop-protection franchise — and its underlying patents have been expiring in key markets since 2022, with core patents rolling off through 2026. Generics are already showing up in the numbers: lower partner orders for the diamide chemistry and deliberate pricing cuts on Rynaxypyr. S&P Global downgraded FMC to junk (BB+) in late 2025, citing the weakened credit profile and that patent cliff.

A cyclical downturn is survivable for a moat that remains intact. A patent cliff that steadies the price of your flagship product is moat erosion — and that is precisely the kind of stress a contrarian buy cannot survive. Even in a turnaround, FMC is filling a structural hole where the revenue floor is lower than it used to be.

Leverage does the rest

The balance sheet explains why the market still prices the equity so cheaply — around 0.5x sales and roughly book value — despite improved cash flow. Net debt is about $3.8 billion against total equity of roughly $1.7 billion, a roughly 2.6x debt-to-equity ratio, and rising interest expense is one of management's stated reasons earnings keep falling. The dividend was already slashed about 83% in late 2025, to $0.08 a quarter, ending the income story that once propped up the stock.

The plan to pay down roughly $1 billion in debt is real and worth taking seriously — the India sale, the rimisoxafen license, a property sale-leaseback, and the Tessenderlo check. But note what the "cheap" valuation is really telling you: a small market cap sitting under a much larger debt load. A $1.6 billion company carrying $7.5 billion of gross debt is not the same value proposition as a $1.6 billion company on a clean balance sheet.

What would make this a bottom

I don't think investors need to chase the rally here. Run FMC through the tests, and the current view fails them. The value-versus-growth case isn't there — "cheap" next-year earnings are still falling, down over half at the guided midpoint, so the multiple compresses even as the denominator shrinks. The moat test is a live patent cliff. And fundamentals are not stabilizing; they're guided to worsen first. On the evidence, the market's distressed pricing is not yet wrong, and the burden of proof sits with the bulls, not the bears.

The earliest checkpoint is the fourth quarter, which management guides back to modest growth — up about 4% in revenue and roughly flat earnings. That is the first honest place to look for an inflection. Until guidance stops being cut and ex-India revenue turns positive year over year, treat the 20% snap-back as a short squeeze doing what short squeezes do, not as confirmation that the farming turned. The numbers will argue for the bottom when they're ready; the chart arguing it today is the part you can't trust.